Lower respiratory tract infections: Etiology, current treatment, and experience with fluoroquinolones

Clinical Microbiology and Infection

Volumn 4, Issue SUPPL. 2, 1998, Pages 2S42-2S50

  Rubinstein, Ethan ^a   Carbon, Claude ^b   Rangaraj, Manickam ^c   Santos, Jose Ignatio ^d   Thys, Jean P ^e   Veyssier, Pierre ^f  

^a SHEBA MEDICAL CENTER   (Israel)

^b BICHAT HOSPITAL   (France)

^c SANOFI   (France)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e ERASME HOSPITAL   (Belgium)

^f Centre Hospitalier Compiegne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

BRONCHITIS; CHRONIC BRONCHITIS; CONFERENCE PAPER; CYSTIC FIBROSIS; DISEASE CLASSIFICATION; HOSPITAL INFECTION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; PNEUMONIA; PRIORITY JOURNAL;

EID: 7144254447     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1998.tb00693.x     Document Type: Conference Paper

References (59)

1. Pozzi E, Oliva A. Oral cephalosporins: clinical results in lower respiratory tract infections. In Moellering RC Jr, ed. Oral cephalosporins. Antibiotic chemotherapy. Basel: Karger, 1995: 123-44.
2. Honeybourne D, Baldwin DR. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother 1992; 30: 249-60.
3. Niederman MS. An approach to empiric therapy of nosocomial pneumonia. Med Cin North Amer 1994; 78: 1123.
4. Nathwani D, Tillotson G, Davey P. Sequential antimicrobial therapy - the role of quinolones. J Antimicrob Chemother 1997; 39: 441-6.
5. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
6. Johnson JA. Pathogenesis of bacterial infections of the respiratory tract. Br J Biomed Sci 1995; 52: 157-61.
7. Cole P, Wilson R. Host-microbial relationships in respiratory disease. Chest 1989, 95: 217s-21s.
8. Pellegrino MB, Privitera A, Primavera A, Puntotieri Nicoletti A, Stefani S, Nicoleta G. Microbiological considerations of the enological agents of lower respiratory tract infections. J Chemother 1992; 4: 211-15.
9. Sarubbi FA, Myers JW, Williams JJ, Shell CG. Respiratory infections caused by Branhamella catarrhalis Am J Med 1990; 88(suppl 5A): 9s-14s.
10. Vogel F. A guide to the treatment of lower respiratory tract infections. Drugs 1995; 50: 62-72.
11. Cazzola M, Vinciguerra A, Beghi GF, et al. Comparative evaluation of the clinical microbiological efficacy of coamoxyclav vs. cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J Chemother 1995, 5: 432-41.
12. Tjonk FR, Willems FT. Ofloxacin in the treatment of acute exacerbations of chronic bronchitis: efficacy and safety of a once-daily regimen Curr Ther Res 1993; 54: 265-71.
13. Watanabe K, Yoseda M, Ishibashi T, et al. Clinical efficacy of ofloxacin in acute exacerbation of chronic respiratory disease. Drugs 1995; 49(suppl 2): 448-50.
14. Perez-Gonzalvo ME, Mosquera-Pestana JA, Ramos D, et al. Ofloxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbation of chronic bronchitis. Clin Ther 1996: 18: 440-7
15. Chodosh S. Use of quinolones for the treatment of acute exacerbations of chronic bronchitis. Am J Med 1991; 91(suppl A): 93-100.
16. DeAbate CA, for the SPAR Multicenter ABECB Study Group. Treatment of acute bacterial exacerbations of chronic bronchitis with sparfloxacin and ofloxacin [abstract LM9]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana. Washington, DC: American Society for Microbiology, 1996: 282.
17. Habib MP, Gentry LO, Rodriguez-Gomez G, Morowitz W, Williams RR. A multicenter, randomized study comparing the efficacy and safety of oral levofloxacin vs. cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis [abstract LM2]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana. Washington DC: American Society for Microbiology, 1996: 280.
18. DeAbate CA, Russell M, McElvaine P, Fowler CL. Safety and efficacy of levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997; 42: 206-13.
19. Finch RG. The role of new quinolones in the treatment of respiratory tract infections. Drugs 1995; 49(suppl 2): 144-51.
20. Schleupner CJ, Cobb DK. A study of the etiologies and treatment of nosocomial pneumonia in a community-based teaching hospital. Infect Control Hosp Epidemiol 1992; 13: 515-25.
21. Smilack JD, Wilson WR, Cockerill FR III. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. Mayo Clinic Proc 1991; 66: 1270-80.
22. Khan FA. Quinolones and macrolides; roles in respiratory infections. Hosp Pract 1993; 28: 149-62.
23. Hendershot EF. Fluoroquinolones. Infect Dis Clin North Am 1995; 9: 715-30.
24. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994; 38: 547-57.
25. Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Arch Intern Med 1989; 149: 2269-73.
26. Gentry LO, Rodrigueq-Gomez G, Kohler RB, Khan FA, Rytel MW. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. Am Rev Respir Dis 1992; 145: 31-5.
27. Petermann W. Ofloxacin in lower respiratory tract infections. Infection 1991; 19(suppl 7): S372-7.
28. Fass RJ. Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. Br Soc Antimicrob Chemother 1993; 32(suppl A): 17-27.
29. Anon. Fourth consensus conference on antimicrobial therapy: respiratory tract infections. Med Mal Infect 1992; 22(special issue): 47-50.
30. Bartlett JG. Community-acquired pneumonia: current status. Infect Dis Clin Pract 1995; 4(suppl 4): S223-31.
31. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618-24.
32. Baltch AL, Smith RP, Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob Agents Chemother 1995; 39: 1661-6.
33. Brown SD, Barry AL, Fuchs PC, Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and CP-99,219, and a new fluoroquinolone [abstract F235]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California. Washington DC: American Society for Microbiology, 1995: 154.
34. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994, 47: 677-700.
35. Dubois J, St-Pierre C. An in vitro susceptibility study of trovafloxacin against Legionella spp. [abstract E75]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana. Washington DC: American Society for Microbiology, 1996-95.
36. Felmingham D, Robbins MJ, Mathias I, et al. Results of a European multicentre study of the comparative in vitro susceptibility of Gram-negative bacteria to levofloxacin. Clin Microbiol Infect 1997; 3(suppl 2): 283.
37. Hammerschlag MR, Qumei KQ, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 1573-4.
38. Montanari MP, Prenna M, Mingoia M, Ripa S, Varaldo PE. Inhibitory and bactericidal activities of trovafloxacin and four fluoroquinolones against clinical isolates from Italian hospitals [abstract E84]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana. Washington DC: American Society for Microbiology, 1996: 96.
39. Roblin PM, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae [abstract 2244]. In: Program and abstracts of the 20th International Congress of Chemotherapy, Sydney, Australia, 1997: 28.
40. Sefton AM, Maskell JP, Seymour AC, Minassian M, Williams JD. Comparative in vitro activity of CP-99219, a new quinolone, against respiratory pathogens. J Antimicrob Chemother 1996; 37: 803-8.
41. Ball AP, Tillotson GS. Lower respiratory tract infection therapy - the role of ciprofloxacin. J Inter Med Res 1995; 23: 315-27.
42. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991; 325: 520-1.
43. Cooper B, Lawlor M. Pneumococcal bacteraemia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med 1989; 87: 475.
44. Righter J. Pneumococcal meningitis during intravenous ciprofloxacin therapy. Am J Med 1990; 88: 548.
45. Gordon JJ, Kauffman CA. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacm. Am J Med 1990; 89: 383-4.
46. Nielsen PB, Husfeldt P, Egede F. Ofloxacin vs erythromycin in community-acquired pneumonia in general practice. Drugs 1993; 45(suppl): 421.
47. Plouffe JF, Herbert MT, File TM Jr, et al. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob Agents Chemother 1996; 40: 1175-9.
48. Carbon C, Lèophonte P, Petitpretz P, Chauvin JP, Hazebroucq J. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia. Antirmcrob Agents Chemother 1992; 36: 833-9.
49. Baquero F, Cantœn R. In vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother 1996; 37(suppl A): 1-18.
50. Honeybourne D, Greaves I, Baldwin DR, Andrews JM, Harris M, Wise R. The concentration of sparfloxacin in lung tissues after single and multiple oral doses. Int J Antimicrob Agents 1994; 4: 151-5.
51. Aubier M, Lode H, Gialdroni-Grassi G, et al. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. J Antimicrob Chemother 1996; 37(suppl A): 73-82.
52. Portier H, May TH, Proust A, French Study Group. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996; 37(suppl A): 83-91.
53. Örtqvist A, Valtonen M, Cars O, et al. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin Chest 1996; 110: 1499-506.
54. Lode H, Höffken G, Olschewski P, et al. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother 1987; 31: 1338-42.
55. Okazaki O, Kojima C, Hakusui H, Nakashima M. Enantio-selective disposition of ofloxacin in humans. Antimicrob Agents Chemother 1991; 35: 2106-9.
56. Fish DN, Chow CT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101-19.
57. Wagai N, Tawara K. Quinolone antibacterial-agent-induced cutaneous photoxicity: ear swelling reactions in Balb/c mice. Toxicol Lett 1991; 58: 215-23.
58. Fogarty CM. A noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of community-acquired pneumonia in adults. Poster Presentation, 19th International Congress of Chemotherapy, Montreal, Canada, Canadian Infection Disease Society, 1995.
59. File TM, Segreti J, Dunbar L, et al. A multicentre, randomised study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adules with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-72.